About
Bradford
  HIV/AIDS
Articles
  Alternative
Therapies
  HIV/AIDS
Videos
  HIV/AIDS
Links
  HIV/AIDS
News

Introduction:
Positively Positive
- Living with HIV
  Out
About
HIV
  Resume/
Curriculum Vitae:
HIV / AIDS Involvements
  Biography   HIV/AIDS
News Archive
HIV/AIDS News spacer.gif Bradford McIntyre Positively Positive Living with HIV/AIDS spacer.gif
spacer.gif
   
AIDS Awareness Red Ribbon


CATIE, Canada’s source for HIV and hepatitis C information. - www.catie.ca

Long-acting lenacapavir combined with other long-acting drugs for HIV treatment

November 12, 2026

CATIE News

  • Researchers studied a novel combination of long-acting (LA) HIV treatments

  • A combination of LA lenacapavir + LA cabotegravir was used by 46 people with HIV

  • Taken over two years, these drugs were highly effective at suppressing HIV

The first long-acting (LA) HIV treatment regimen is a combination of two drugs:

  • cabotegravir – an integrase inhibitor

  • rilpivirine – a non-nucleoside reverse transcriptase inhibitor (NNRTI), also known as a non-nuke

This combination, sold as Cabenuva in Canada and some other high-income countries, was initially approved for once-monthly dosing administered by a healthcare provider as intramuscular injections deep into the buttocks. Subsequent clinical trials used higher doses of both drugs and found that the combination could suppress HIV when administered via deep intramuscular injections into the buttocks every two months.

Another LA drug used to treat HIV is lenacapavir, sold as Sunlenca. This drug belongs to a class of anti-HIV medicines called capsid inhibitors. According to its manufacturer, Gilead Sciences, Sunlenca is approved for the treatment of multidrug-resistant HIV-1 in people who are heavily treatment experienced and whose current regimen is failing. Healthcare providers inject lenacapavir subcutaneously (under the skin), usually in the abdomen, every six months.

As mentioned earlier, Cabenuva is a combination of two LA drugs—cabotegravir + rilpivirine. Studies have found that Cabenuva is effective in people who have difficulty taking pills or who have challenges with treatment adherence. However, some people with HIV have partial or complete resistance to rilpivirine, which may make this drug unsuitable for them. 

To address these challenges, doctors in Canada, the U.S. and other countries have been using combinations of the following LA drugs in some patients who have difficulty adhering to treatment: 

  • LA lenacapavir + LA cabotegravir, with or without LA rilpivirine

Reports on people with HIV who have used these combinations over the long term are lacking, leaving physicians with limited evidence to guide prescribing and administration. Now, that is beginning to change.

In San Francisco

A team of researchers in San Francisco recently reported positive results with 46 people with HIV who were treated with LA lenacapavir + LA cabotegravir. Some participants also received LA rilpivirine. 

The average profile of participants prior to study entry was as follows:

  • age – 49 years

  • cisgender males – 32; cisgender females – 10; nonbinary or gender queer – 3; transgender female – 1

  • major ethno-racial groups: Hispanic – 35%; Black – 35%; white – 24%

  • low CD4+ cell count (200 or fewer CD4+ cells/mm3) – 58%

It is important to note that prior to entering the study, participants had the following issues:

  • 52% were unable to achieve viral suppression with the regimens they were on

  • 41% had unstable housing

  • 33% were using methamphetamine

In addition, 72% of participants had HIV that was resistant to rilpivirine. The distribution of LA treatment was as follows:

  • lenacapavir + cabotegravir – 29 people

  • lenacapavir + cabotegravir + rilpivirine – 17 people

The researchers analyzed data collected for up to 100 weeks.

Results

Prior to receiving lenacapavir, 52% of participants had a viral load of 200 copies/mL or higher. After starting LA lenacapavir + LA cabotegravir (with or without rilpivirine), their viral loads became suppressed. Most (80%) achieved viral suppression within six weeks after initiating LA treatment. By week 12, all participants who had a detectable viral load before the study had achieved viral suppression.

Participants who already had a suppressed viral load before the study maintained a suppressed viral load after switching to LA HIV treatment. 

Safety

Overall, the study findings confirmed the safety of LA HIV treatment observed in other studies.

People receiving injectable LA HIV treatment commonly develop temporary pain, redness and/or swelling at the injection site. This occurred in almost 60% of participants in the San Franciso study.

Lenacapavir can sometimes also cause small lumps, or nodules, at the injection site. This occurred in 40% of participants in the present study and can take weeks or in some cases months to resolve.

Bear in mind

The data used in this study were originally collected for another purpose and then later reanalyzed for the present study. This type of analysis can potentially lead to inadvertent biases that may affect how the results are interpreted. However, the findings are in line with those reported in smaller studies in the past. 

The results from the present study are encouraging and could help inform the design of larger studies being planned by the U.S. National Institutes of Health (NIH). The results could also help physicians when they are considering treatment options for patients who have challenges with adherence to oral medications.

—Sean R. Hosein

Resources

Ottawa scientists explore the use of long-acting cabotegravir + rilpivirine in pregnancy – CATIE News

Chicago study looks at ways of bringing people with HIV back into care – CATIE News

Long-acting injectable HIV treatment highly effective in people with a detectable viral load and adherence challenges – CATIE News

REFERENCES:

  1. Gistand NL, Mishra IC, Hunter K, et al. Long-acting lenacapavir and cabotegravir and viral suppression among people with HIV. JAMA Network Open. 2026 Oct 1;9(10):e2638182.  
  2. Gilead Sciences Canada. Sunlenca (lenacapavir). Product Monograph. 12 August 2026.

From Canadian AIDS Treatment Information Exchange (CATIE).
This content was originally published by CATIE, Canada’s source for HIV and hepatitis C information.

Source: CATIE: https://www.catie.ca/catie-news/long-acting-lenacapavir-combined-with-other-long-acting-drugs-for-hiv-treatment

For more information visit CATIE's Information Network at www.catie.ca


Back to…
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News


For more HIV and AIDS News visit…

Positively Positive - Living with HIV/AIDS: HIV/AIDS News Archive
HIV and AIDS News sorted by Month & Year


…positive attitudes are not simply ‘moods’

Site Map

Contact Bradford McIntyre.

Copyright © 2003 - 2026 Bradford McIntyre. All rights reserved.

DESIGNED TO CREATE HIV & AIDS AWARENESS

spacer.gif